Citalopram (Escitalopram)

A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.

Also Known As:

Networked: 1478 relevant articles (242 outcomes, 460 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Fava, Maurizio: 35 articles (12/2015 - 10/2005)
2.	Rush, A John: 32 articles (08/2015 - 01/2005)
3.	Stein, Dan J: 27 articles (01/2015 - 01/2002)
4.	Trivedi, Madhukar H: 26 articles (07/2014 - 01/2006)
5.	Wisniewski, Stephen R: 23 articles (07/2014 - 01/2006)
6.	Pollock, Bruce G: 18 articles (12/2015 - 03/2002)
7.	Kasper, Siegfried: 15 articles (01/2016 - 01/2004)
8.	McGuffin, Peter: 14 articles (12/2014 - 01/2009)
9.	Uher, Rudolf: 14 articles (12/2014 - 01/2009)
10.	Thase, Michael E: 14 articles (03/2011 - 01/2002)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 07/01/2014 - "We investigated which factors can best predict relapse in older patients with major depressive disorder (MDD) who have achieved remission with escitalopram. " 01/01/2013 - "The results indicate that escitalopram is the most cost-effective pharmacologic treatment strategy for both regional health services compared with all SSRIs and all SNRIs used in the first-line treatment of major depressive disorder." 01/01/2007 - "Our aim in this study was to investigate the efficacy of escitalopram, a proven antidepressant, on symptoms of anxiety in patients with major depressive disorder (MDD). " 01/01/2003 - "Escitalopram 10 or 20 mg/day produced significantly greater improvements in standard measurements of antidepressant effect (Montgomery-Asberg Depression Rating Scale [MADRS], Clinical Global Impressions Improvement and Severity scales [CGI-I and CGI-S] and Hamilton Rating Scale for Depression [HAM-D]) in patients with major depressive disorder (MDD) than placebo in several 8-week, placebo-controlled, randomised, double-blind, multicentre studies. " 03/01/2011 - "Postmenopausal women with major depressive disorder who did not respond to acute, double-blind treatment with escitalopram or desvenlafaxine achieved modest, continued improvement with long-term, open-label desvenlafaxine therapy. "
2.	Anxiety Disorders (Anxiety Disorder) 10/01/2005 - "Escitalopram has proven efficacy in the short-term treatment of generalized social anxiety disorder (SAD). " 11/01/2002 - "Citalopram appears to be effective and well tolerated in this group of children and adolescents with depressive or anxiety disorders and a high degree of comorbidity. " 08/01/2007 - "Escitalopram appears to be effective in depression and several anxiety disorders, including social anxiety disorder and generalized anxiety disorder, conditions in which it also appears reasonably well tolerated. " 01/01/2002 - "In this naturalistic setting, citalopram appeared to be a well-tolerated and effective treatment for a range of anxiety disorders in adolescents." 09/01/2002 - "Results of this study suggest that citalopram may be a safe and effective treatment for generalized social anxiety disorder, including patients who have failed to tolerate or respond to a prior treatment trial."
3.	Depressive Disorder (Melancholia) 01/01/1985 - "The relationship between improvement (percentage reduction in total score on the Montgomery-Asberg Depression Rating Scale) and serum level of citalopram indicated a lower limit of effect in endogenous depression at about 100 nM, corresponding to an average dose of 15 mg. Marked improvement was seen in ten patients with steady state levels in the range 70 to 335 nM. The ten nonendogenously depressed patients had steady state levels from 15 to 620 nM; complete remission was seen in the three with the lowest levels (15-25 nM). " 01/01/1999 - "The results of this study indicate that citalopram is safe and effective in the treatment of depressed patients with melancholia, and is associated with a favorable side effect profile and a potentially rapid onset of action." 05/01/2015 - "Following escitalopram treatment, improvement in apathy significantly correlated with improvement in disability measures, while change in the rest of the depressive syndrome did not. " 12/01/1999 - "Citalopram was significantly more effective than placebo in the treatment of moderate-to-severe major depression, especially symptoms of depressed mood and melancholia, with particularly robust effects shown at doses of 40 and 60 mg/day. " 12/01/1999 - "Patients randomly assigned to 40 mg/day and 60 mg/day of citalopram showed significantly greater improvement than placebo on all efficacy measures, as well as on the HAM-D symptom clusters measuring depressed mood, melancholia, cognitive disturbance, and psychomotor retardation. "
4.	Panic Disorder (Panic Attack) 11/01/2003 - "The frequency of panic attacks was statistically significantly improved (p =.04), and the increase in percentage of patients with zero panic attacks reached borderline significance (p =.051), in the escitalopram-treated group relative to the placebo-treated group. " 01/01/2009 - "Compared the efficacy of REAC and Es-Citalopram in the treatment of simultaneous coexistence of Panic Disorder with Major Depression in 9-weeks open label naturalistic study. " 09/01/2008 - "On the whole, numerous clinical data indicate that escitalopram, 10-20 mg/d, is an effective and well-tolerated first-line treatment option for the management of panic disorder, GAD, social anxiety and OCD. " 01/01/2006 - "Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD." 11/01/2003 - "This study evaluated the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder. "
5.	Stroke (Strokes) 10/02/1993 - "We conclude that serotoninergic neurotransmission plays an important part in post-stroke pathological crying and that citalopram is an effective and well-tolerated treatment." 09/05/2013 - "The number of proliferating neural progenitor cells and the distance of neuroblast migration from the sub-ventricular zone toward the ischemic cortex were significantly greater in citalopram-treated mice at 7 days after stroke. " 09/01/2013 - "Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo." 02/01/2010 - "When compared with patients who received placebo or underwent Problem Solving Therapy, stroke patients who received escitalopram showed improvement in global cognitive functioning, specifically in verbal and visual memory functions. " 01/01/2014 - "Although these results should be considered preliminary, the authors found that both escitalopram and PST were effective in preventing new onset of post-stroke GAD. "

Related Drugs and Biologics

1.	Citalopram (Escitalopram)
2.	Serotonin (5 Hydroxytryptamine)
3.	venlafaxine (Effexor)
4.	Paroxetine (Paxil)
5.	Sertraline (Zoloft)
6.	duloxetine (Cymbalta)
7.	Bupropion (Wellbutrin)
8.	Fluoxetine (Prozac)
9.	Antidepressive Agents (Antidepressants)
10.	Nortriptyline (Aventyl)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Stents
4.	Injections
5.	Oral Administration